lncRNA-ACS1 marker and its application in the preparation of products for diagnosis, screening or evaluation of acute coronary syndrome

By developing the lncRNA-ACS1 marker, the problems of insufficient sensitivity and specificity in ACS diagnosis were solved, an efficient non-invasive detection method was provided, and the accuracy of early diagnosis of ACS was significantly improved.

CN120118991BActive Publication Date: 2025-09-16梅州市人民医院
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510366155.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-03-26
Publication Date
2025-09-16
Estimated Expiration
2045-03-26

AI Technical Summary

Technical Problem

Existing technologies lack highly sensitive and specific non-invasive biomarkers for ACS diagnosis, making early diagnosis difficult. Traditional methods such as electrocardiograms and biomarkers have limitations and high false positive rates.

Method used

A new lncRNA-ACS1 marker was used to verify its significant expression in patients with acute coronary syndrome through high-throughput sequencing and qRT-PCR, and a fluorescence quantitative PCR kit was developed to detect lncRNA-ACS1 expression in peripheral blood mononuclear cells and plasma exosomes.

Benefits of technology

The diagnostic sensitivity and specificity of ACS were improved, providing a more accurate evaluation method. The diagnostic value of lncRNA-ACS1 in plasma exosomes was better than that in mononuclear cells, and ROC curve analysis showed high diagnostic value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120118991B_ABST
    Figure CN120118991B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedical technology, and discloses a long non-coding RNA marker and its application in the preparation of a product for diagnosis, screening or evaluation of acute coronary syndrome. The acute coronary syndrome lncRNA marker provided by the present invention is for detecting the expression level of lncRNA-ACS1 in plasma exosomes. Compared with existing traditional biomarkers, the marker of the present invention has better tissue specificity and stability, greatly improving the sensitivity and specificity of the diagnosis of acute coronary syndrome, and providing a more accurate evaluation method for clinical diagnosis. The marker involved in the present invention has important value in the clinical diagnosis of acute coronary syndrome (AUC=0.902, 95%CI:0.862-0.943). When the Cutoff value is 0.0066, the sensitivity is 90% and the specificity is 74%, which is suitable for promotion and application.
Need to check novelty before this filing date? Find Prior Art

Claims

1. Use of a reagent for detecting the expression level of a lncRNA marker for acute coronary syndrome in the preparation of a product for diagnosing or screening acute coronary syndrome, characterized in that: The lncRNA marker is lncRNA-ACS1; the sequence of the lncRNA-ACS1 is shown as SEQ ID No. 1; and the detection sample of the product is plasma exosomes.

2. The use according to claim 1, characterized in that: The product includes a fluorescent quantitative PCR reagent for detecting the expression level of lncRNA-ACS1.

3. The use according to claim 2, characterized in that: The fluorescent quantitative PCR reagent for detecting the expression level of lncRNA-ACS1 is a primer pair for specifically detecting the expression level of lncRNA-ACS1. The primer pair consists of a forward primer and a reverse primer. The forward primer is 5'-CAGAAGCACATCCAGATTCAAGG-3'; the reverse primer is 5'-TGGTGTGTAAAATGTTTGCCC-3'.

4. The use according to claim 1, characterized in that: The products include chips, preparations, test strips or test kits.

5. The use according to claim 4, characterized in that: The kit also includes a primer pair for specifically detecting the expression level of GAPDH and a fluorescent dye.

6. The use according to claim 5, characterized in that: The fluorescent dye is SYBR Green fluorescent dye or TBGreen fluorescent dye; the primer pair for specifically detecting the expression level of GAPDH consists of a GAPDH forward primer and a GAPDH reverse primer, the GAPDH forward primer is 5'-ATGACATCAAGAAGGTGGTG-3', and the GAPDH reverse primer is 5'-CATACCAGGAAATGAGCTTG-3'.

Citation Information

Patent Citations

  • IncRNA marker and application thereof in preparation of product for diagnosing, screening or evaluating acute coronary syndrome

    CN117385024A